US Market Access Leverage existing US market approvals and historical US FDA activity, including Chlorthalidone ANDA filings and past US launches, to target US generics customers. Position Unichem as a cost-competitive end-to-end supplier with integrated API and formulation capabilities to speed time-to-market for US clients. Develop partnerships with US distributors and contract manufacturers to expand footprint in developed markets.

Integrated API Advantage Backwards integration to API manufacturing enables end-to-end supply for formulators, offering reliable quality and potential cost advantages. This makes Unichem an attractive single-source partner for customers seeking API plus finished dosage forms, especially in markets with stringent supply-chain and regulatory requirements. Target mid- to large-scale generic and specialty pharma customers looking to consolidate suppliers.

Regulatory Risk Readiness Regulatory risk exposure, highlighted by the European Commission fine in the Perindopril case, creates an opening to discuss robust compliance, quality systems, and audit-ready documentation as a differentiator. Offer regulatory support and supply assurance for customers importing into stringent markets, reducing their compliance burdens and risk.

Acquisition Synergy Ipca's 2023 acquisition of Unichem hints at potential collaboration and scale advantages across manufacturing and distribution networks. Sales opportunities include cross-selling API and finished dosage capacity to Ipca's customer base and leveraging any shared distribution channels to reach new geographies.

Digital Infrastructure Current tech investments, including SAP, Trend Micro partnership, and other digital tools, signal a drive toward secure, compliant operations. Pitch IT-enabled manufacturing and quality data management, ERP integration, and cybersecurity solutions to pharma clients seeking reliable, audit-ready product development and supply chains.